Senior Principal Scientist
Posted on Apr 5, 2021 by Bristol-Myers Squibb
At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
The Tumor Microenvironment Thematic Research Center (TME TRC) is focused on developing therapeutic targets at the intersection of tumor, stromal and immune biology within the TME with the goal of enhancing responsiveness to checkpoint blockade and targeted therapies. Comprising of scientists across multiple disciplines we are responsible for the biology and translational science necessary to support drug development from target identification through to first in human studies.
We are seeking a highly motivated and talented individual to lead the formed tissue/IHC biomarker team within the Translational Development Group at Bristol Myers Squibb (Redwood City, CA) TME TRC. This team is responsible for all tissue-based biomarker assays from program inception through First in Human studies, in alignment with clinical development objectives, as well as clinic-ready patient selection and pharmacodynamics biomarker assays for the TME TRC programs. The data generated from this team will influence a broad array of decisions around dose optimization, indication prioritization, and potential drug combinations. The candidate will interact and collaborate with scientists within Translational Development, Clinical Development, Discovery, Translational Bioinformatics, and our external business partners both Academic and CRO.
The successful candidate must be able to set and understand priorities in a local and matrixed environment, must be a team player with a collaborative spirit, and capable of building and maintaining networks within and outside the organization. The candidate must have a strong background in tissue-based biomarker assays and their applications in translational/clinical programs as well as experience with and understanding of tumor immuno-oncology related disciplines.
Responsibilities will include, but are not limited to, the following:
Lead a group of scientists to drive the adaptation, execution, integration and validation of cutting-edge tissue-based assay technologies (eg IHC, ISH, Multiplex IF/IHC, spatial transcriptomics) and digital image analysis to develop translational biomarkers in oncology from preclinical through phase 2.
Serve as a subject matter expert in immunohistochemistry and other tissue-based assays development and fit-for-purpose validation
Evaluation of reagents, controls, samples and data (internal and external), including comparisons between methodologies.
Successfully develop and implement novel multiplexed IHC and IF assays for application to slide-based tissues samples to address complex biological challenges across the TME TRC portfolio.
Contribute to development of assays that may progress to patient selection and/or companion diagnostics.
Collaborate closely with scientists from TME-TRC and bioinformatics to customize image analysis workflows to support biomarker analysis for early and late stage programs.
Serve as SME and/or oversee out-sourced (CRO) work packages in support of discovery and translational projects as well as for the strategy and portfolio team supporting early development assets.
Provide input to translational biomarker and clinical sample strategies in relation to tissue-based assay technologies
Develop SOPs, validation plans, final reports, presentations and publications summarizing data.
Effectively collaborate in highly matrixed organization to drive the advancement of therapeutic candidates.
Partner with discovery, preclinical scientists and translational strategy project teams to guide tissue-based assay selection
Actively participate in internal and external scientific meetings through presentations and critical evaluation of both internal results and emerging scientific literature.
PhD, MD, or MD/PhD in biology, pharmacology, or related discipline with at least 8 years of hands on experience in the industry, contract research organization, or pharma setting is required in oncology.
Subject matter expert in the development and validation, troubleshooting and implementation of assays using various advanced technologies that may not be currently in clinical use.
Must have experience with cutting-edge tissue-based assay technologies (eg IHC, ISH, Multiplex IF/IHC, spatial transcriptomics) and ability to apply their experience to biomarker development.
Must have extensive experience using digital image analysis software/digital pathology such as Halo, Visiopharm, Aperio systems.
CRO experience, knowledge of CLIA/GCLP practices is a plus, but not required.
Understanding of fit for purpose assay validation principles for clinical assays.
Excellent organization skills and familiarity with a fast-paced work environment.
Collaborative spirit and ability to thrive in a matrixed environment
Prior line management experience
Ability to clearly communicate and operate in a highly matrixed environment
Proven track record of handling multiple high priority tasks in parallel with internal and external collaborators
Excellent written and verbal communication skills and experience with Excel and PowerPoint.
Experience in mentoring scientists, and a proven ability to build an effective organization by attracting, retaining and developing high-caliber scientists
Set up alerts to get notified of new vacancies.